Hypertrophic Cardiomyopathy
Clinical research in hypertrophic cardiomyopathy includes both obstructive and non-obstructive forms, with attention to symptomatic HCM and left ventricular outflow tract obstruction. The studies focus on functional status, exercise capacity, and cardiac symptom burden.
- Symptomatic obstructive hypertrophic cardiomyopathy
- Symptomatic non-obstructive hypertrophic cardiomyopathy
- Left ventricular outflow tract obstruction
- Exercise capacity
Work in this area also includes pediatric hypertrophic cardiomyopathy, reflecting interest across age groups and disease presentations.
Heart Failure
Research activity in heart failure with reduced ejection fraction is centered on patients with severe systolic dysfunction and persistent symptoms despite background guideline-directed medical therapy. The clinical focus is on heart failure outcomes, health status, and functional limitation.
- Heart failure with reduced ejection fraction
- Severely reduced ejection fraction
- Symptomatic heart failure
- Heart failure outcomes
This area connects with broader efforts in cardiovascular disease management for patients with chronic impairment in cardiac performance.
Cardiac Function and Symptom Relief
The sponsor’s trials place strong emphasis on measures of cardiac function, including exercise tolerance, health status, and relief of symptoms associated with cardiomyopathy and heart failure. These outcomes reflect a focus on daily functioning and patient-reported burden.
- Maximal exercise capacity
- Health status
- Symptom burden
- Functional capacity
Assessment of these domains is central to research in patients with chronic structural heart disease and impaired cardiac performance.
Safety and Tolerability in Cardiac Disease
Several studies address the safety and tolerability of therapies used in hypertrophic cardiomyopathy and heart failure, including long-term follow-up and use in pediatric and adult populations. The research landscape includes monitoring of treatment-related cardiac effects and ongoing management of chronic disease.
- Long-term safety
- Tolerability
- Pediatric cardiology
- Adult cardiology
These studies support development in specialty cardiovascular therapeutics for patients with persistent structural and functional heart disease.
Myosin-Targeted Cardiac Therapy
The sponsor’s funded research is closely associated with cardiac myosin inhibition and other myosin-targeted therapies for hypertrophic cardiomyopathy and heart failure. This therapeutic domain includes investigation of treatments aimed at improving cardiac mechanics and reducing obstruction-related symptoms.
- Cardiac myosin inhibition
- Myosin-targeted therapies
- Cardiac mechanics
- Obstruction-related symptoms
Research in this field spans both structural heart disease and chronic cardiovascular disorders with unmet clinical needs.
